IRIDEX Corporation reports preliminary unaudited FY 2025 results

IRIDEX Corporation reported that it has released preliminary, unaudited results for its fourth fiscal quarter and full fiscal year ended January 3, 2026.

Rhea-AI Filing Summary

IRIDEX Corporation reported that it has released preliminary, unaudited results for its fourth fiscal quarter and full fiscal year ended January 3, 2026. The company shared these operational and financial figures in a press release dated January 12, 2026, which is attached as Exhibit 99.1. The disclosure is being furnished rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IRIDEX Corporation (IRIX) disclose in this 8-K filing?

IRIDEX Corporation furnished an update stating that it announced preliminary, unaudited operational and financial results for its fourth fiscal quarter and full fiscal year ended January 3, 2026, through a press release attached as Exhibit 99.1.

Which period do IRIDEX Corporation’s preliminary results cover?

The preliminary, unaudited results cover IRIDEX Corporation’s fourth fiscal quarter and full fiscal year ended January 3, 2026.

Where can investors find the detailed preliminary results for IRIDEX (IRIX)?

The detailed preliminary, unaudited operational and financial results are contained in the company’s press release dated January 12, 2026, which is included as Exhibit 99.1 to this report.

Are the preliminary results in this IRIDEX 8-K considered filed with the SEC?

No. The company states that this information is being furnished, not filed, so it is not subject to certain liabilities of Section 18 of the Exchange Act and is not incorporated into other securities filings unless specifically referenced.

What securities of IRIDEX Corporation are listed on a national exchange?

IRIDEX Corporation’s common stock, par value $0.01 per share, trades on the Nasdaq Capital Market under the symbol IRIX.

Who signed the IRIDEX Corporation 8-K covering the preliminary results?

The report was signed on behalf of IRIDEX Corporation by Patrick Mercer, Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 09:11 AM Learn about SEC filing dates

0001006045false00010060452026-01-122026-01-12

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM 8-K CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	January 12, 2026
Date of Report (date of earliest event reported)
IRIDEX CORPORATION
(Exact name of registrant as specified in its charter)
Delaware		000-27598	77-0210467
(State or other jurisdiction of incorporation or organization)		(Commission File Number)	(I.R.S. Employer Identification Number)
1212 Terra Bella Avenue Mountain View, California 94043
(Address of principal executive offices, including zip code)
(650) 940-4700
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of Class		Trading Symbol		Name of Exchange on Which Registered
Common Stock, par value $0.01 per share		IRIX		Nasdaq Capital Market

Item 2.02. Results of Operations and Financial Condition.

On January 12, 2026, IRIDEX Corporation (the "Company") announced its preliminary, unaudited operational and financial results for its fourth fiscal quarter and full fiscal year ended January 3, 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated January 12, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			IRIDEX CORPORATION
	By:		/s/ Patrick Mercer
			Patrick Mercer
			Chief Executive Officer
Date: January 12, 2026

-3-